| Code | CSB-RA808531MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MWTx-01, targeting TMPRSS6 (transmembrane protease serine 6), also known as matriptase-2. TMPRSS6 is a type II transmembrane serine protease that plays a critical role in systemic iron homeostasis by cleaving membrane-bound hemojuvelin, a co-receptor for bone morphogenetic proteins. This cleavage suppresses hepcidin expression, the master regulator of iron metabolism, thereby promoting iron absorption and release from storage sites. Dysregulation of TMPRSS6 activity is associated with iron metabolism disorders, including iron-refractory iron deficiency anemia when loss-of-function mutations occur, and iron overload conditions when the protease is overactive.
MWTx-01 represents a therapeutic antibody designed to inhibit TMPRSS6 activity, making this biosimilar a valuable research tool for investigating iron metabolism pathways, hepcidin regulation mechanisms, and potential therapeutic interventions for disorders characterized by hepcidin deficiency and iron overload. This antibody supports studies examining TMPRSS6 function in cellular and molecular contexts relevant to hematological research and metabolic disease investigation.
There are currently no reviews for this product.